• Inicio
  • Formações
  • Formação à Medida
  • News & Trends
  • Sobre nós
  • Contacto

EC MDR Guidance on New Safety and Clinical Performance Summary

The main purpose of this document is to provide guidance on the presentation,content and validation of the SSCP. The word “shall” is used when there is a corresponding “shall” in the MDR, otherwise “should” or “recommended” etc. is used indicating the interpretation of the MDR.

 

MDCG 2019-9 Summary of safety and clinical performance A guide for manufacturers and notified bodies

News & Trends

Procurar

Recentes

  • FDA Biosimilar Development – Q&A Guidance: Q&As on Biosimilar Development and the BPCI Act
  • NDSG workplan 2026-2028 : Data and AI in medicines regulation
  • New guidance on the conduct of clinical trials during public health emergencies
  • Nova lei regula ensaios clínicos de medicamentos para uso humano em Portugal
  • FDA draft guidance :“New Clinical Investigation Exclusivity: 3-Year Exclusivity for Drug Products – Questions and Answers.”
  • webinar INTELIGÊNCIA ARTIFICIAL NA INDÚSTRIA FARMACÊUTICA :IA EM CONTEXTO GxP (Annex 11, 22, EU AI Act , GAMP®)
  • GESTÃO da DISPONIBILIDADE do MEDICAMENTO: “Formação muito útil !
  • IMDRF Playbook for Medical Device Regulatory Reliance Programs

91 257 00 03 (Chamada para a rede móvel nacional)
info@formiventos.com

  • Follow
  • CLIENTES & TESTIMONIALS
  • ASSOCIAÇÕES OFICIAIS
  • CERTIFICAÇÕES E CREDITAÇÕES
  • ADVISORY BOARD
  • Política de Privacidade
  • Contacto